Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
British Journal of Cancer|September 30, 2010
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive valueA Michlmayr, T Bachleitner-Hofmann, S Baumann, et al.
Blood|December 15, 1995
Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of responseM Cazzola, D Messinger, V Battistel, et al.
Annals of Hematology|December 3, 2013
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patientsM Fiegl, R Stauder, M Steurer, et al.
ESMO Open|January 5, 2021
A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohortP Dubsky, L Van't Veer, M Gnant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2015
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtypeM Gnant, I Sestak, M Filipits, et al.
International Journal of Antimicrobial Agents|October 16, 2010
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patientsS Perkhofer, C Lass-Flörl, M Hell, et al.
Leukemia Research|October 10, 1998
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemiaW Hilbe, U Apfelbeck, M Fridrik, et al.
ESMO Open|August 9, 2021
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6M Filipits, M Rudas, C F Singer, et al.
British Journal of Cancer|October 1, 2014
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analysesT Brodowicz, I Lang, Z Kahan, et al.
Leukemia & Lymphoma|March 26, 2002
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-CW Hilbe, T Kühr, U Apfelbeck, et al.
Pageof 12